Pfizer Inc. said an appeals court ruled in its favor in a patent infringement case over the drug maker's anti-convulsant Neurontin. The dispute relates to Pfizer's allegation of patent infringement over forms of gabapentin, the active ingredient in Neurontin. Pfizer says the patent does not begin expiring until 2017. In 2004, however, generic manufacturer Teva Pharmaceutical Industries Ltd. began shipping gabapentin tablets, which it says is the generic equivalent of Pfizer's Neurontin.
September 24, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Pfizer Inc. said on Sept. 21 an appeals court ruled in its favor in a patent infringement case over the drug maker’s anti-convulsant Neurontin.
The dispute relates to Pfizer’s allegation of patent infringement over forms of gabapentin, the active ingredient in Neurontin.
Presented by BigVoodoo
The New York Law Journal honors attorneys and judges who have made a remarkable difference in the legal profession in New York.
The African Legal Awards recognise exceptional achievement within Africa s legal community during a period of rapid change.
Consulting Magazine identifies the best firms to work for in the consulting profession.
Wisniewski & Associates, LLC seeks attorney licensed in NJ and NY with 2-5 years experience for its multi-state real estate, land use, ...
Labor Relations CounselUS-GA-AtlantaJob ID: 2024-0042Type: 4 (Exempt, Bargaining Unit 1 (EB)# of Openings: 1Category: Contract Administratio...
